Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary12/22/2015
Annual option exercised to extend collaboration First development candidate advancing to Phase 2/3 development in 2016 Additional programs expected in 2016 PHILADELPHIA , Dec. 22, 2015 (GLOBE NEWSWIRE) --   Medgenics, Inc. (NYSE:MDGN) today announced the annual renewal of its major research
Toggle Summary12/16/2015
PHILADELPHIA , Dec. 16, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), today announced the initiation of a research program to evaluate the use of TARGT EPO TM alone or in combination with iron restriction to ameliorate erythropoiesis in Beta Thalassemia Intermedia (non-transfusion
Toggle Summary11/25/2015
PHILADELPHIA , Nov. 25, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that Michael Cola , President and CEO, will participate in a fireside chat discussion at the 27 th Annual Piper Jaffray Healthcare Conference in New York . The event will take place at 3:30 p.m.
Toggle Summary10/22/2015
Acquired Phase 2-Ready CNS asset, NFC-1 First of pipeline of potential programs from CHOP collaboration Results of Phase 1 GREAT trial to be presented at American Academy of Child and Adolescent Psychiatry (AACAP) meeting Completed Successful Public Offering for $46M in gross proceeds PHILADELPHIA
Toggle Summary10/15/2015
PHILADELPHIA , Oct. 15, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Thursday, October 22, 2015 at 8:30 a.m. ET to discuss third quarter 2015 financial results. In order to participate in the conference call, please dial (844) 466-4113
Toggle Summary10/13/2015
PHILADELPHIA , Oct. 13, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the following appointments: Liza Squires , MD joins as Vice President Research and Development, Therapeutic Area Head, Neuroscience David Fitts , PhD joins as Vice President and Head, Statistical
Toggle Summary10/12/2015
PHILADELPHIA , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the completion of an underwritten public offering of 7,078,250 shares of its common stock, including 923,250 shares sold pursuant to the full exercise of an option previously granted to the underwriters
Toggle Summary10/01/2015
PHILADELPHIA , Oct. 1, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 6,155,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $6.50 per share. In connection with the offering, Medgenics has also
Toggle Summary09/30/2015
PHILADELPHIA , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the
Toggle Summary09/09/2015
Strong Efficacy Signal Established in Genetically Identified Subset of ADHD Patients Development will Include Neuropsychiatric Symptoms of 22q11.2 Deletion Syndrome PHILADELPHIA , Sept. 9, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the acquisition of neuroFix